- Oxford study finds increased risks of dementia two years after contracting COVID-19
- 14 hospitals in Japan issued a “blood warning”
- Inconspicuous vitamin K can effectively inhibit cell ferroptosis
- What is the practical significance when WHO declares monkeypox as a public health event of international concern?
- Immune cells use hunger hormones to help heal skin infections and wounds
- New mRNA cancer vaccine designed to target lymph nodes for stronger immune response
Self-amplified mRNA vaccine-saRNA vaccine safe and effective in first trial
Self-amplified mRNA vaccine-saRNA vaccine safe and effective in first trial. The first clinical trial, a new generation of self-amplified mRNA vaccine-saRNA vaccine is safe and effective.
With the widespread use of mRNA vaccines all over the world, mRNA technology has demonstrated powerful capabilities. Recently, a new generation of mRNA vaccine called self-amplified RNA vaccine (saRNA) has begun to attract attention.
Compared with traditional mRNA vaccines, the new saRNA vaccine can self-amplify in the body, so it only needs a very low dose to produce high-level antigens through self-amplification and cause a stronger immune response.
Recently scientists from Imperial College London conducted the world’s first clinical trial of this new type of saRNA COVID-19 vaccine. The clinical trial results showed that the vaccine can produce a protective immune response in 87% of vaccinators, even if the injection dose is far low. In traditional mRNA. Moreover, no short-term safety issues have been observed.
At present, the clinical trial results have been released on the preprint platform of The Lancet.
Compared with traditional mRNA vaccines, the mRNA sequences delivered by saRNA vaccines add replicable sequences. After entering the cells, they can be like viruses and can use host cells to replicate themselves, thereby achieving antigenicity at very low injection doses. High expression to achieve the ability to generate a strong immune response.
Comparison of traditional mRNA vaccine and saRNA vaccine
In this clinical trial, 192 18-45-year-old participants received different doses of saRNA vaccine, separated by 4 or 14 weeks. The dose range is 0.1 micrograms to 10 micrograms of saRNA, 87% of people will develop antibodies against the new coronavirus. Participants had very low side effects, the most common being chills and muscle pain, and no one had an allergic reaction.
Professor Robin Shattock, the head of the COVID-19 vaccine vaccine project at Imperial College London, said that the COVID-19 virus variants that can be immune to escape are now appearing constantly. It is expected that in the next ten years, the world will continue to need the COVID-19 vaccine. This clinical trial has proven that the new coronavirus mRNA vaccine based on saRNA technology is safe and can produce a protective immune response.
In addition, saRNA technology can not only be used to develop COVID-19 vaccines, but also has the potential to prevent other infectious diseases, such as rabies, Ebola, etc. The research team said that saRNA technology can also be used to develop cancer vaccines.
Professor Robin Shattock
Professor Robin Shattock also said that the biggest feature of saRNA technology is its ultra-low dose. Compared with the 100 micrograms of Moderna’s mRNA vaccine and the 30 micrograms of BioNTech/Pfizer’s mRNA vaccine, saRNA only requires 0.1 to 10 micrograms.
This ultra-low injection dose has three important advantages:
1. With greater manufacturing potential, the same origin and production equipment can produce more vaccines;
2. Because of the low dosage, the risk of side effects is reduced;
3. The feature of low dose can be used in combination with other vaccines.
The research team said that the technology is currently being improved to produce a more consistent and stronger immune response at low doses. It is reported that they recently started a new clinical trial using their upgraded version of saRNA technology.
(source:internet, reference only)